News

Verve Therapeutics licensed some of the base-editing technology VERVE-101 is based on from Beam Therapeutics. In October, Verve's collaboration partner, Eli Lilly, handed Beam $250 million upfront ...
We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...
Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.
About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...
Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.
Verve Therapeutics, Inc. (NASDAQ:VERV) is a clinical-stage company focused on revolutionizing the treatment of cardiovascular disease through innovative gene-editing approaches.
Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive agreement for Lilly ...
Verve Therapeutics is part of the Zacks Medical - Drugs industry. Karyopharm Therapeutics (KPTI), another stock in the same industry, closed the last trading session 3% lower at $0.67.
Eli Lilly plans to acquire Verve for up to $1.3 billion. Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. Eli Lilly (NYSE: LLY) and Verve ...
Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session.